Trial Profile
A Genome-Wide Association Study in Patients Experiencing Musculoskeletal Adverse Events on NCIC CTG Trial MA.27 Evaluating Aromatase Inhibitors as Adjuvant Therapy in Early Breast Cancer. A Collaboration Between the NIH Pharmacogenetics Research Network and the RIKEN Yokohama Institute Center for Genomic Medicine
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Exemestane (Primary) ; Anastrozole; Celecoxib
- Indications Early breast cancer
- Focus Pharmacodynamics; Pharmacogenomic
- 19 Feb 2020 Status changed from active, no longer recruiting to completed.
- 11 Jul 2016 Status changed from withdrawn prior to enrolment to active, no longer recruiting.
- 23 Mar 2016 New trial record